Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Merck KGaA’s Drug Tops Roche’s Avastin for Colon Cancer

Merck KGaA said its cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin.

In a trial among 342 patients with advanced colon cancer lacking certain genetic mutations, those receiving Erbitux had a median survival of 33.1 months, compared with 25.6 months for those treated with Avastin, according to a Merck statement of data presented today at a cancer conference in Amsterdam. Both drugs were combined with chemotherapy.

The findings suggest that Erbitux, already approved in Europe as a treatment for patients with so-called KRAS wild-type tumors, may have a role in a sub-group of patients with so-called RAS wild-type cancer. Merck, based in Darmstadt, Germany, is studying the results of two other trials for evidence of the same trend, with a view to seeking regulatory approval in Europe for the drug in patients with RAS wild-type cancer.

“Of course, we are highly interested to get the right treatment to the right patients,” Oliver Kisker, head of clinical development at Merck’s Serono unit, said in a telephone interview. The additional 7.5 months is “very impressive, very interesting.”

Erbitux and Avastin are so-called monoclonal antibodies designed to block a protein that causes cancer cells to multiply. By coupling Erbitux or Avastin with a trio of cell-killing chemotherapy drugs, doctors aim both to stop tumors from growing and to shrink them.


Among the 16 percent of patients with a mutant form of RAS colon cancer, those who received Erbitux had a median overall survival of 20.3 months compared with 20.6 months for those who received Avastin, according to the Merck report.

The study missed its main goal of shrinking tumors more than Avastin did in patients with the mutant form of KRAS colon cancer, Merck said in June.

Erbitux generated sales for Merck of 887 million euros ($1.2 billion). The German company sells the medicine outside North America. Bristol-Myers Squibb Co., based in New York, and Indianapolis-based Eli Lilly & Co. are the partners for the drug in the U.S.

Germany’s Merck isn’t related to U.S. drugmaker Merck & Co. based in Whitehouse Station, New Jersey.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.